Ipragliflozin-induced improvement of liver steatosis in obese mice may involve sirtuin signaling

Figure 1 Body weights and liver-to-body weight ratios of obese mice treated with or without ipragliflozin and their lean littermates. A: Body weights of mice in the lean, obese (ob/ob), ob/ob + ipragliflozin 3 mg/kg, and ob/ob + ipragliflozin 10 mg/kg groups at the end of therapy; B: Liver-to-body weight ratios of mice in the lean, ob/ob, ob/ob + ipragliflozin 3 mg/kg, and ob/ob + ipragliflozin 10 mg/kg groups at the end of therapy. NS: Not significant; ob/ob: Obese; Ipra: Ipragliflozin. n = 8.